Investigational · not FDA approved

Editorially reviewed · Last updated July 25, 2026 · How we review

Retatrutide FDA Approval Timeline 2026-2028

Key findings

Retatrutide is not FDA-approved. Lilly has said it plans to file in Q1 2027, putting a possible decision in late 2027 or 2028 if the application is accepted.
A completed Phase 3 trial does not itself make a drug approved or commercially available.
The FDA must accept the application, review efficacy, safety, manufacturing, and labelling, then decide whether to approve it.
Timelines can move if new safety data, manufacturing questions, or additional analyses are required.

Retatrutide FDA Approval Timeline 2026-2028

Q: When will retatrutide be FDA approved?

There is no confirmed FDA approval date. On July 23, 2026 Lilly said it plans to submit a Biologics License Application in the first quarter of 2027 — superseding its earlier guidance of a 2026 submission. The FDA then takes about 60 days to decide whether to accept the filing, and review after acceptance is typically 6–10 months (priority vs standard). That puts the earliest realistic decision window in late 2027 to the first half of 2028. See Projected Milestones and What Would Change the Timeline.

Q: What is the retatrutide FDA approval timeline for 2026–2028?

2026: pivotal obesity trial TRIUMPH-1 reported (May 21), then TRIUMPH-2 and TRIUMPH-3 (July 23); remaining Phase 3 readouts broaden the label. Q1 2027: Lilly plans to submit its BLA to the FDA. Late 2027–2028: typical FDA review after filing, then possible approval and staggered international filings. Nothing is approved yet — this page tracks confirmed milestones vs projections.

Q: Is retatrutide FDA approved?

No. As of July 2026, retatrutide is not FDA approved for any indication, and no application has been filed yet. It remains an investigational drug.What has happened: its pivotal Phase 3 obesity trial, TRIUMPH-1, reported topline results on May 21, 2026 (28.3% average weight loss at 80 weeks) and is now marked complete on ClinicalTrials.gov, followed by TRIUMPH-2 and TRIUMPH-3 on July 23, 2026. Lilly said the same day that it plans to submit a Biologics License Application in Q1 2027. Reporting a successful trial is not approval — the FDA still has to receive, accept, and review the application.

Q: Has the pivotal retatrutide obesity trial reported yet?

Yes. TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026: average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension. 45.3% of participants on the highest dose lost 30% or more of their body weight. The trial is listed as Completed on ClinicalTrials.gov, with a primary completion date of April 6, 2026.This matters for the timeline because TRIUMPH-1 is the trial the obesity filing rests on. TRIUMPH-2 and TRIUMPH-3 have since reported (July 23, 2026), and the readouts still outstanding (TRIUMPH-5, the MASH trial) broaden the potential label — they are not blocking the submission Lilly has planned for Q1 2027. Dose-by-dose results are on our Clinical Trials & Results page.

Last updated: July 25, 2026

Current Status

Retatrutide is not FDA approved as of July 2026. It cannot be legally prescribed or purchased outside of clinical trials, and there is no brand name or FDA decision date. What changed on July 23, 2026: alongside two new Phase 3 readouts, Lilly said it plans to submit a Biologics License Application (BLA) for retatrutide to the FDA in the first quarter of 2027. That is the first time the company has named a filing window.

Eli Lilly's Phase 3 trial program (TRIUMPH and TRANSCEND-T2D) has now reported results from five registration trials — including the pivotal obesity trial that anchors the weight-management filing.

TRIUMPH-1 (pivotal general obesity, topline May 21 2026) — the registration trial for the obesity indication. 2,339 participants, 80 weeks; 28.3% average weight loss at the highest dose, and 30.3% at 104 weeks in a pre-specified extension. The trial is now marked Completed on ClinicalTrials.gov (NCT05929066, primary completion April 6 2026).
TRIUMPH-2 (obesity with type 2 diabetes, topline July 23 2026) — 1,152 participants, 80 weeks; 20.8% weight loss at 12 mg, and A1C down 1.5% at 12 mg (1.6% at 9 mg) from a 7.7% baseline.
TRIUMPH-3 (obesity with established cardiovascular disease, topline July 23 2026) — 1,949 randomized, 80 weeks; 22.6% weight loss at 12 mg.
TRIUMPH-4 (knee osteoarthritis, Dec 2025) — 28.7% weight loss.
TRANSCEND-T2D-1 (type 2 diabetes, Mar 19 2026) — A1C reduction of 1.7-2.0% and 16.8% weight loss.

With a Q1 2027 BLA and a standard ~10-month review (or ~6 months if the FDA grants priority review), a first approval decision lands in late 2027 or early 2028 — later than the 2027 window implied by Lilly's earlier "submit in 2026" guidance. The remaining readouts (TRIUMPH-5, weight maintenance, and the MASH trial) determine which additional indications ride along with that filing; they are not gating the obesity submission, which TRIUMPH-1 anchors.

Timeline at a Glance

Below is a summary of where retatrutide stands in the FDA approval process. Items are marked as confirmed (based on published data or official announcements) or projected (based on analyst estimates and typical regulatory timelines).

Confirmed Milestones

Date	Milestone	Status
2019-2020	Phase 1 first-in-human studies begin	Completed
2022	Phase 1 results published in The Lancet	Completed
2023	Phase 2 obesity results published in NEJM	Completed
2023	Phase 2 type 2 diabetes results published in The Lancet	Completed
2023	TRIUMPH Phase 3 program launched	Completed
December 2025	TRIUMPH-4 Phase 3 results — 28.7% weight loss in knee OA	Completed
March 19, 2026	TRANSCEND-T2D-1 results — A1C -1.7% to -2.0%, 16.8% weight loss	Completed
May 21, 2026	TRIUMPH-1 topline — the pivotal obesity registration trial. 28.3% weight loss at 80 weeks (2,339 participants); 30.3% at 104 weeks in extension	Completed
June 6-10, 2026	ADA 86th Scientific Sessions — full TRIUMPH-1 + TRANSCEND-T2D-1 panel	Completed
July 23, 2026	TRIUMPH-2 and TRIUMPH-3 topline. 20.8% weight loss and up to -1.6% A1C in obesity with T2D; 22.6% weight loss in obesity with established CVD	Completed
July 23, 2026	Lilly names its filing window: BLA submission planned for Q1 2027	Announced
2026 (H2)	Remaining TRIUMPH Phase 3 readouts (TRIUMPH-5 head-to-head, MASH, weight maintenance)	Upcoming

Phase 3 Readouts and the Filing They Support

Every registration readout maps to an indication Lilly can file for. This is the scoreboard that actually determines the NDA:

Trial	Population	Readout	Headline Result	Filing It Supports
TRIUMPH-1	Obesity / overweight (no diabetes)	May 21, 2026	28.3% at 80 wks; 30.3% at 104 wks	Obesity — the core filing
TRIUMPH-4	Obesity + knee osteoarthritis	Dec 2025	28.7% weight loss	Knee osteoarthritis
TRIUMPH-3	Obesity + established CVD	Jul 23, 2026	22.6% at 12 mg (80 wks)	Cardiovascular / weight management
TRANSCEND-T2D-1	Type 2 diabetes	Mar 19, 2026	A1C -1.7% to -2.0%; 16.8% weight loss	Type 2 diabetes
TRIUMPH-2	Obesity + type 2 diabetes (nested OSA)	Jul 23, 2026	20.8% at 12 mg; A1C -1.5% at 12 mg	Obesity in T2D; OSA
MASH / MASLD trial	Metabolic liver disease	Expected 2026	—	MASH (differentiated filing)

The obesity submission no longer waits on an unread trial: TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 have all reported. What the remaining readouts change is the breadth of the label, not whether Lilly can file.

What Would Change the Timeline

These are scenarios, not forecasts. Lilly has now named a filing quarter (Q1 2027) but not a submission date or an FDA acceptance date; each row is a what-if based on public trial status and typical FDA clocks.

If this happens…	Likely effect on approval window	Confidence
Lilly submits the BLA in Q1 2027 as stated on July 23, 2026	FDA acceptance typically ~60 days, then a standard ~10-month or priority ~6-month review — decision clusters in late 2027 to H1 2028	Medium-high — the quarter is now company guidance, but calendar slip is common
FDA grants priority review	Shortens the review clock from ~10 months to ~6 after acceptance — a decision in late 2027 rather than the first half of 2028	Low — no Fast Track / Breakthrough public designation yet
The Q1 2027 filing slips a quarter	Pushes a first decision toward mid-2028; availability follows later	Medium — filing dates move more often than they hold
Complete Response Letter (CRL) on first review	Adds months for resubmission; 2028 availability becomes more likely	Unknown — no filing yet
Brand name + manufacturing scale lag after approval	Script availability can lag approval by months (tirzepatide precedent)	High historically for this class

Projected Milestones

Important: Unless noted as "confirmed," the dates below are analyst projections based on Lilly's public statements and typical regulatory timelines. Actual timelines may differ.

Projected Date	Milestone	Basis for Estimate
Q1 2027	Regulatory submission (BLA)	Stated by Lilly on July 23, 2026 alongside the TRIUMPH-2 and TRIUMPH-3 results: it plans to submit a Biologics License Application to the FDA in Q1 2027. This supersedes the earlier "submit in 2026" guidance from the Q4 2025 earnings call (Feb 4, 2026)
~60 days after submission	FDA filing decision	The FDA decides whether to accept the application for review
6-10 months after acceptance	FDA decision	Based on typical PDUFA review timeline (6 months for priority, 10 for standard)
Late 2027 - H1 2028	Potential FDA approval	Assuming a Q1 2027 submission, acceptance, and a standard or priority review without delays

What Has Happened So Far

Phase 1 (2019-2022)

Retatrutide entered first-in-human studies between 2019 and 2020. Results from these early safety and dose-finding studies were published in The Lancet in 2022, demonstrating that the triple agonist mechanism (GIP, GLP-1, and glucagon receptors) was tolerable in humans and showing promising early weight loss signals.

Phase 2 (2022-2023)

Phase 2 trial results generated significant attention in the medical community:

Obesity trial results were published in the New England Journal of Medicine in 2023, showing weight loss of up to 24.2% at the highest dose over 48 weeks.
Type 2 diabetes trial results were published in The Lancet in 2023, showing meaningful improvements in blood sugar control alongside substantial weight loss.

These results were widely covered in medical media and prompted Eli Lilly to advance retatrutide into a large-scale Phase 3 program.

Phase 3: The TRIUMPH Program (2023-present)

Eli Lilly launched the TRIUMPH clinical trial program in 2023. This is a series of Phase 3 trials studying retatrutide across multiple conditions:

TRIUMPH-1: Obesity (basket trial with nested OSA and OA protocols)
TRIUMPH-2: Obesity in type 2 diabetes population (with nested OSA)
TRIUMPH-3: Weight management in cardiovascular disease population
TRIUMPH-4: Obesity with knee osteoarthritis (completed — results December 2025)
Additional trials covering MASLD (metabolic dysfunction-associated steatotic liver disease), cardiovascular/renal outcomes, chronic low back pain, and weight maintenance
TRANSCEND program: Dedicated type 2 diabetes trials (separate from TRIUMPH)

TRIUMPH-4 was the first Phase 3 trial to report results, announced in December 2025. It met its primary endpoints, showing an average weight loss of 28.7% in participants with obesity and knee osteoarthritis. This was widely viewed as a positive signal for the broader program.

For detailed trial-by-trial tracking, see our Clinical Trials & Results page.

What to Watch in 2026

Five of the major Phase 3 readouts have now reported — including TRIUMPH-1, the pivotal obesity trial the whole weight-management filing rests on, plus TRIUMPH-2 and TRIUMPH-3 on July 23, 2026. The remaining readouts determine which additional indications make the first round of FDA filings, not whether the filing happens. The date to watch now is the Q1 2027 BLA submission.

Already reported (and cleared primary endpoints):

TRIUMPH-1 — pivotal general obesity (May 21, 2026) — 28.3% weight loss at 80 weeks, 30.3% at 104 weeks in a pre-specified extension; 45.3% of participants on the highest dose lost 30% or more of their body weight
TRIUMPH-4 — knee osteoarthritis + obesity (Dec 2025) — 28.7% weight loss at 68 weeks
TRANSCEND-T2D-1 — type 2 diabetes (Mar 19, 2026) — A1C -2.0%, 16.8% weight loss at 40 weeks
TRIUMPH-2 — obesity with type 2 diabetes, nested OSA protocol (July 23, 2026) — 20.8% weight loss at 12 mg over 80 weeks; A1C -1.5% at 12 mg (-1.6% at 9 mg)
TRIUMPH-3 — obesity with established cardiovascular disease (July 23, 2026) — 22.6% weight loss at 12 mg over 80 weeks
ADA 86th Scientific Sessions (Jun 6-10, 2026, New Orleans) — the full TRIUMPH-1 + TRANSCEND-T2D-1 panel, the most detailed public presentation of the Phase 3 data — see our ADA 2026 retatrutide coverage

Still expected:

TRIUMPH-5 (head-to-head vs tirzepatide, NCT06662383): Phase 3 obesity efficacy comparison; primary outcome is percent change in body weight (~800 participants). Primary completion expected December 2026.
Additional TRANSCEND-T2D trials: Long-term diabetes outcomes.

Beyond 2026 (long-horizon outcomes trials):

TRIUMPH-Outcomes (NCT06383390): long-term CV/kidney outcomes CVOT (~10,000 participants). Primary completion expected February 2029. CV primary is a composite of cardiovascular death, non-fatal MI, non-fatal stroke, and heart-failure events; kidney composite as registered.
Phase 3 MASLD master protocol (NCT07165028, see Retatrutide and fatty liver): multi-agent MASLD program that includes retatrutide — not a dedicated retatrutide-only liver trial. Primary completion expected August 2030 (full study completion ~August 2032).

Each readout is covered on our News page as results are announced.

How the FDA Approval Process Works

For readers unfamiliar with FDA drug approval, here is how the remaining steps typically unfold:

Step 1: Phase 3 Trial Completion

The drug maker completes large-scale trials demonstrating safety and efficacy. Retatrutide is currently in this stage, with the core weight-management readouts (TRIUMPH-1, -2, -3, -4 and TRANSCEND-T2D-1) now complete.

Step 2: BLA Submission

Eli Lilly compiles all clinical data into a marketing application — for retatrutide, a Biologics License Application (BLA) — and submits it to the FDA. The FDA then has 60 days to decide whether to accept the application for review (called the "filing decision").

Stated by Lilly: Q1 2027 (announced July 23, 2026, superseding the "submit in 2026" guidance given on the Q4 2025 earnings call, February 4, 2026).

Step 3: FDA Review

Once the NDA is accepted, the FDA assigns a Prescription Drug User Fee Act (PDUFA) target date. This is the deadline by which the FDA aims to complete its review.

Standard review: 10 months from NDA acceptance
Priority review: 6 months from NDA acceptance (granted for drugs offering significant improvements over existing treatments)

Retatrutide has no publicly announced Fast Track designation, Breakthrough Therapy designation, or other expedited pathway. A standard 10-month review is the baseline assumption, though the FDA could grant priority review given the drug's novel mechanism.

Step 4: Advisory Committee Meeting (Possible)

The FDA may convene an advisory committee of outside experts to review the data and vote on whether the drug should be approved. This step is not required for every drug.

Step 5: FDA Decision

The FDA issues one of three decisions:

Approval — The drug can be marketed and prescribed
Complete Response Letter (CRL) — The FDA identifies issues that must be resolved before approval
Refuse to File — The application is incomplete (rare at this stage)

How Retatrutide Compares to Similar Drug Approvals

Eli Lilly and Novo Nordisk have recently brought several GLP-1 receptor agonist drugs through the FDA process. These timelines provide context for what to expect with retatrutide:

Drug	Indication	NDA Submitted	FDA Approved	Review Time
Mounjaro (tirzepatide)	Type 2 diabetes	May 2021	May 2022	~12 months
Zepbound (tirzepatide)	Obesity	April 2023	November 2023	~7 months
Wegovy (semaglutide)	Obesity	December 2020	June 2021	~6 months

Zepbound and Wegovy both received relatively fast reviews for obesity indications. If retatrutide follows a similar pattern, approval could come within 6-12 months of NDA filing, rather than the full 10-month standard timeline.

However, retatrutide is a first-in-class triple agonist (targeting GIP, GLP-1, and glucagon receptors simultaneously), which may lead to more cautious FDA review compared to drugs with established mechanisms.

Which Indications Will Be Filed First?

Eli Lilly is studying retatrutide across a broad range of conditions. Based on the TRIUMPH program structure and Lilly's track record with tirzepatide, the most likely filing sequence is:

Obesity — Expected to be the first indication filed, with the BLA planned for Q1 2027. TRIUMPH-1, the pivotal obesity trial, reported on May 21, 2026, and TRIUMPH-2 (obesity in type 2 diabetes) and TRIUMPH-3 (obesity with established cardiovascular disease) both reported on July 23, 2026 — so the core evidence package for this filing is in hand.
Type 2 diabetes — May be filed simultaneously or shortly after, supported by the TRANSCEND-T2D program (TRANSCEND-T2D-1 reported March 19, 2026). Note that TRIUMPH-3 is the cardiovascular-disease population, not the diabetes trial.
Additional indications — Knee osteoarthritis, sleep apnea, MASLD, cardiovascular outcomes, and chronic low back pain would follow based on their respective trial timelines

This mirrors how Lilly handled tirzepatide: Mounjaro was approved for diabetes first (May 2022), followed by Zepbound for obesity (November 2023).

Brand Name

Eli Lilly has not announced a brand name for retatrutide. The drug is currently referred to only by its generic name.

Based on Lilly's precedent with tirzepatide, retatrutide will likely receive separate brand names for different indications:

Tirzepatide became Mounjaro for type 2 diabetes and Zepbound for obesity
Retatrutide is expected to follow the same pattern with distinct brand names per indication

Brand names are typically announced closer to the FDA approval date or during the NDA review period.

What Happens After FDA Approval

Even after FDA approval, there are several steps before retatrutide becomes widely available:

Prescriptions and Availability

Lilly will need to scale manufacturing, which typically begins well before approval
Initial supply may be limited, similar to the early availability challenges seen with Mounjaro and Zepbound
Prescriptions will initially require an in-person or telehealth consultation with a licensed provider

Insurance Coverage

Insurance coverage is not automatic upon FDA approval
Private insurers will set their own coverage policies, which can take months to finalize
Medicare and Medicaid coverage depends on the approved indication and ongoing policy decisions
The Medicare Inflation Reduction Act drug price negotiation program may eventually apply

Pricing Context

Current GLP-1 drug pricing provides context for what retatrutide might cost, though Lilly has not announced pricing:

Drug	Monthly Cost (Manufacturer Programs)	List Price
Ozempic / Wegovy (Novo Nordisk)	$199-499/month	$1,000+/month
Mounjaro / Zepbound (Eli Lilly)	$349-499/month via LillyDirect	$1,000+/month
Medicare negotiated price (GLP-1s)	~$245/month	N/A

GoodRx has offered introductory pricing of $199/month for certain GLP-1 medications. Pricing trends across the GLP-1 class have been downward due to competition and government negotiation.

For ongoing pricing updates, see our Cost & Access page.

Frequently Asked Questions

When will retatrutide be FDA approved?

There is no confirmed FDA approval date. On July 23, 2026 Lilly said it plans to submit a Biologics License Application in the first quarter of 2027 — superseding its earlier guidance of a 2026 submission. The FDA then takes about 60 days to decide whether to accept the filing, and review after acceptance is typically 6–10 months (priority vs standard). That puts the earliest realistic decision window in late 2027 to the first half of 2028. See Projected Milestones and What Would Change the Timeline.

What is the retatrutide FDA approval timeline for 2026–2028?

2026: pivotal obesity trial TRIUMPH-1 reported (May 21), then TRIUMPH-2 and TRIUMPH-3 (July 23); remaining Phase 3 readouts broaden the label. Q1 2027: Lilly plans to submit its BLA to the FDA. Late 2027–2028: typical FDA review after filing, then possible approval and staggered international filings. Nothing is approved yet — this page tracks confirmed milestones vs projections.

Is retatrutide FDA approved?

No. As of July 2026, retatrutide is not FDA approved for any indication, and no application has been filed yet. It remains an investigational drug.

What has happened: its pivotal Phase 3 obesity trial, TRIUMPH-1, reported topline results on May 21, 2026 (28.3% average weight loss at 80 weeks) and is now marked complete on ClinicalTrials.gov, followed by TRIUMPH-2 and TRIUMPH-3 on July 23, 2026. Lilly said the same day that it plans to submit a Biologics License Application in Q1 2027. Reporting a successful trial is not approval — the FDA still has to receive, accept, and review the application.

Has the pivotal retatrutide obesity trial reported yet?

Yes. TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026: average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension. 45.3% of participants on the highest dose lost 30% or more of their body weight. The trial is listed as Completed on ClinicalTrials.gov, with a primary completion date of April 6, 2026.

This matters for the timeline because TRIUMPH-1 is the trial the obesity filing rests on. TRIUMPH-2 and TRIUMPH-3 have since reported (July 23, 2026), and the readouts still outstanding (TRIUMPH-5, the MASH trial) broaden the potential label — they are not blocking the submission Lilly has planned for Q1 2027. Dose-by-dose results are on our Clinical Trials & Results page.

When will retatrutide be available?

Retatrutide is not expected to be available by prescription until late 2027 at the earliest, and more likely 2028. Lilly said on July 23, 2026 that it plans to submit its Biologics License Application in Q1 2027; FDA review typically takes 6-12 months after the filing is accepted, and manufacturing scale-up can add more time on top of approval.

Can I get retatrutide now?

The only legal way to receive retatrutide today is by enrolling in one of Eli Lilly's clinical trials. Retatrutide is not available through pharmacies, telehealth services, or compounding pharmacies.

Any website claiming to sell retatrutide is operating outside of FDA regulations. "Research chemical" versions sold online are unregulated, unverified, and potentially dangerous.

What will retatrutide cost?

Eli Lilly has not announced pricing for retatrutide. Based on current GLP-1 drug pricing, analyst estimates suggest a list price of $1,000+ per month, with manufacturer discount programs potentially bringing costs to $300-500 per month for eligible patients.

Actual pricing will depend on the competitive landscape at the time of launch, insurance negotiations, and government pricing policies. See our Cost & Access page for ongoing updates.

How is retatrutide different from Ozempic or Mounjaro?

Retatrutide is a triple agonist, targeting three receptors: GIP, GLP-1, and glucagon. Ozempic (semaglutide) targets only GLP-1, while Mounjaro (tirzepatide) targets GIP and GLP-1. The additional glucagon receptor activity is believed to contribute to retatrutide's higher weight loss results in clinical trials. For a detailed comparison, see our Retatrutide vs Mounjaro page.

What is the retatrutide release date?

There is no confirmed release date for retatrutide. Based on Lilly's stated plan to submit a BLA in Q1 2027 and typical FDA review timelines of 6-12 months after acceptance, the earliest realistic availability date is late 2027, more likely 2028. This assumes the FDA accepts the application and completes its review without delays. For international markets (EU, Australia, Canada), availability would likely follow in 2029-2030.

Has retatrutide received Fast Track or Breakthrough Therapy designation?

No Fast Track designation, Breakthrough Therapy designation, or other FDA expedited review pathway has been publicly announced for retatrutide as of February 2026. Lilly may apply for such designations as part of the submission process, but no public confirmation exists.

Which GLP-1 drugs are FDA approved for weight loss?

As of July 2026, the FDA-approved GLP-1 drugs for weight loss (chronic weight management) are: Wegovy (semaglutide injection, Novo Nordisk), Zepbound (tirzepatide injection, Eli Lilly), Saxenda (liraglutide injection, Novo Nordisk), and oral Wegovy (semaglutide tablets, approved December 2025). Retatrutide is not yet approved — Lilly plans to submit its application in Q1 2027, with a potential approval in late 2027 or 2028. CagriSema (cagrilintide + semaglutide) and orforglipron also have pending applications.

Is retatrutide legal?

Retatrutide is a legal investigational drug being developed by Eli Lilly through the standard FDA approval process. It is legal to receive retatrutide as a participant in an authorized clinical trial. However, it is not legal to sell retatrutide as a prescription drug since it has no FDA approval. Gray market "research chemical" versions sold online exist in a legal gray area — they are typically sold labeled "not for human consumption," but using them carries significant health risks and no regulatory protections.

Sources

Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) — TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss
Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) — TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027
ClinicalTrials.gov — NCT05929066 (TRIUMPH-1) — Phase 3, status Completed, primary completion April 6, 2026
Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) — confirmed regulatory submission planned for 2026
Eli Lilly press releases and investor communications
ClinicalTrials.gov (TRIUMPH program trial registrations)
Jastreboff AM, et al. New England Journal of Medicine (2023) — Phase 2 obesity results
Rosenstock J, et al. The Lancet (2023) — Phase 2 type 2 diabetes results
Frias JP, et al. The Lancet (2022) — Phase 1 results
FDA.gov — Drug approval process and PDUFA guidelines

What Is Retatrutide (GLP-3)? — How the triple agonist works
Clinical Trials & Results — Detailed TRIUMPH program tracker
Retatrutide vs Mounjaro — Side-by-side comparison
Side Effects & Safety — What clinical trials have shown
Cost & Access — Pricing, insurance, and how to get it
News & Updates — Chronological tracker of every development

This page is updated as new information becomes available. Bookmark it to stay current on retatrutide's path to FDA approval.

Medical disclaimer: The information on this page is for educational purposes only and is not medical advice. Retatrutide is an investigational drug that has not been approved by the FDA. Do not attempt to obtain or use retatrutide outside of supervised clinical trials. Always consult a qualified healthcare provider before making decisions about medications or weight management. glp3.wiki is not affiliated with Eli Lilly or any pharmaceutical company.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources